Denis Lucquin
Director/Board Member at Cerenis Therapeutics, Inc.
Denis Lucquin active positions
Companies | Position | Start | End |
---|---|---|---|
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Private Equity Investor | 31/07/1991 | - |
Chairman | 31/03/2007 | 30/03/2017 | |
Cerenis Therapeutics, Inc.
Cerenis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cerenis Therapeutics, Inc. discovers, develops and commercializes drugs for the treatment of cardiovascular and metabolic diseases. It focuses on discovery, development, and commercialization of HDL therapies. Cerenis Therapeutics is located in Ann Arbor, MI. | Director/Board Member | 21/11/2011 | - |
Biocleave Ltd.
Biocleave Ltd. BiotechnologyHealth Technology Biocleave Ltd. develops and sells microbial technology for the production of renewable chemicals and biofuels. It also provides biobutanol and other C4 chemical products. The firm also engages in microbiology and metabolic engineering through fermentation and commercial production scale. Its products include biobutanol chemicals and fuel, acetone, and butyric acid. The company was founded by Edward M. Green in 2003 and is headquartered in Abingdon, the United Kingdom. | Director/Board Member | - | - |
EnobraQ SAS
EnobraQ SAS Chemicals: Major DiversifiedProcess Industries EnobraQ SAS develops yeast for the production of chemical compounds. The company was founded on November 13, 2015 and is headquartered in Ramonville-Saint-Agne, France. | Director/Board Member | 18/11/2015 | - |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Director/Board Member | - | - |
Avantium Technologies BV
Avantium Technologies BV Miscellaneous Commercial ServicesCommercial Services Avantium Technologies BV operates as chemical technology company. It offers a breeding ground for revolutionary renewable chemistry solutions. The firm specializes in innovations and technologies for catalytic research and development services and systems. The company was founded in February 2000 and is headquartered in Amsterdam, the Netherlands | Director/Board Member | - | - |
By Design Ltd.
By Design Ltd. Apparel/Footwear RetailRetail Trade By Design Ltd. owns & operates clothing and footwear stores. The company was founded in 1980 and is headquartered in Manchester, GB. | Director/Board Member | - | - |
Career history of Denis Lucquin
Former positions of Denis Lucquin
Companies | Position | Start | End |
---|---|---|---|
AVANTIUM N.V. | Director/Board Member | 18/05/2011 | 31/08/2020 |
ABIONYX PHARMA | Director/Board Member | 31/12/2004 | 31/12/2014 |
░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░ ░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░ | ░░░░░░░░░░ | - |
░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░ ░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░ ░░░░░░░░ ░░ ░░░░░░░░░ ░░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░ | ░░░░░ ░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
Training of Denis Lucquin
Ecole Polytechnique | Undergraduate Degree |
Université Paris Dauphine-PSL | Graduate Degree |
Statistics
International
France | 16 |
United States | 4 |
Belgium | 3 |
Operational
Director/Board Member | 19 |
Undergraduate Degree | 2 |
Chairman | 1 |
Sectoral
Health Technology | 13 |
Process Industries | 5 |
Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 4 |
---|---|
ABIONYX PHARMA | Health Technology |
DBV TECHNOLOGIES | Health Technology |
AVANTIUM N.V. | Producer Manufacturing |
BIOTALYS NV | Process Industries |
Private companies | 20 |
---|---|
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Finance |
BioAmber, Inc.
BioAmber, Inc. Chemicals: SpecialtyProcess Industries BioAmber, Inc. is an industrial biotechnology company, which produces sustainable chemicals. Its proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstock into chemicals for use in everyday products, including plastics, resins, paints, food additives and personal care products. The firm's products include bio-based succinic acid, butanediol and bio-based disodium succinate. The company was founded on October 15, 2008 and is headquartered in Montreal, Canada. | Process Industries |
Novexel SA
Novexel SA Pharmaceuticals: MajorHealth Technology Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France. | Health Technology |
Ablynx NV
Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
Sequoia Pharmaceuticals, Inc.
Sequoia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sequoia Pharmaceuticals discovers and develops unique treatments for viral diseases including HIV/AIDS and HCV-induced hepatitis with a focus on the growing global problem of drug-resistant disease. Most new anti-viral drugs were designed to block the most prevalent form of a pathogen, but these drugs become less potent due to the emergence of drug-resistant mutations. Sequoia's is to discover and develop new antiviral which are active against the most prevalent form of the virus but also anticipates the emergence of drug resistance forms thereby maintaining potency over time. Sequoia's differentiating approach is to identify a constellation of atomic interaction points which are necessary and sufficient for enzymatic function. Sequoia's protease inhibitors have been designed to interact preferentially with only these atoms, thus allowing non-critical mutations to occur without resulting in a decrease in drug potency. The foundation of Sequoia's novel Resistant-Repellent™ technology is a drug discovery tool that enhances the efficiency with which drugs are designed. It is based on an understanding of the chemical and physical nature of the molecular targets, the enzymes and receptors to which drugs bind, combined with an understanding of the molecular mechanisms that cause drug resistance. Sequoia is also discovering and developing a unique series of pharmacokinetic enhancers (PKEs) to work in combination with its own, and its partners', antiviral therapies. These sets of molecules improve the PK of existing therapeutics and reduce interpatient variability. This represents a unique approach to an important need in HIV treatment today. Sequoia is also looking to extend this novel PKE approach to other areas. Its PKEs are designed to inhibit a particular CYP isozyme and therefore change the metabolism of a co-administered therapeutic agent. The combination of PK Enhancer and the therapeutic agent enables reduced dosage and less frequent administration of the therapeutic agent. | Health Technology |
France Biotech Association
France Biotech Association Miscellaneous Commercial ServicesCommercial Services France Biotech Association is an independent association founded in 1997 that brings together healthtech entrepreneurs and their expert partners. The non-profit company is based in Paris, France. The association actively contributes to meeting the many challenges of the healthtech industry, such as companies' financing, innovation-related taxes, regulatory and market access related issues. It offers concrete competition and solutions through its commissions and working groups to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. The French company was founded by Philippe Pouletty, Pascal Brandys, Denis J. Lucquin. | Commercial Services |
DNP Green Technology, Inc.
DNP Green Technology, Inc. Chemicals: Major DiversifiedProcess Industries DNP Green Technology is a stand-alone business devoted to commercialization of technologies related to manufacturing of biologically-derived succinic acid and its derivatives. DNP Green Technology's bio-based succinic acid production process is cost competitive with that of petro-based processes and has the further advantage of being 'green'. DNP's process consumes green house gases (CO2), providing the long term potential to generate carbon credits. Its core technology consists of a proprietary E.coli fermentation process and an integrated downstream process that has been proven at a large scale (80,000 liters). Succinic acid has numerous market applications such as bioplastics & green plasticizers and polyesters & resins. | Process Industries |
CareX SA
CareX SA Pharmaceuticals: MajorHealth Technology CareX SA is a privately held biopharmaceutical company located in Strasbourg, France, that is committed to the discovery and development of innovative, safe and effective medicines for the treatment of diseases linked to the metabolic syndrome. The company was founded in 2001 and is headquartered in Illkirch-Graffenstaden, France | Health Technology |
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | Health Technology |
Neuro3D SA
Neuro3D SA Pharmaceuticals: OtherHealth Technology Neuro3d SA develops pharmaceutical products to treat the central nervous system. Neuro3d has a full pipeline of innovative compounds with new mechanisms of action that have the potential to overcome the limitations of current drug therapies. It leads compound, the atypical antipsychotic ocaperidone, is being investigated in two international double-blind Phase II trials for treatment of schizophrenia. The company was founded in November 2000 and is headquartered in Mulhouse, France. | Health Technology |
Innolion
Innolion Financial ConglomeratesFinance Innolion provides investment services. | Finance |
Cerenis Therapeutics, Inc.
Cerenis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cerenis Therapeutics, Inc. discovers, develops and commercializes drugs for the treatment of cardiovascular and metabolic diseases. It focuses on discovery, development, and commercialization of HDL therapies. Cerenis Therapeutics is located in Ann Arbor, MI. | Health Technology |
Ecole Nationale du Génie Rural des Eaux et Forêts | Consumer Services |
Biocleave Ltd.
Biocleave Ltd. BiotechnologyHealth Technology Biocleave Ltd. develops and sells microbial technology for the production of renewable chemicals and biofuels. It also provides biobutanol and other C4 chemical products. The firm also engages in microbiology and metabolic engineering through fermentation and commercial production scale. Its products include biobutanol chemicals and fuel, acetone, and butyric acid. The company was founded by Edward M. Green in 2003 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Institut National de Recherche Agronomique SA
Institut National de Recherche Agronomique SA Miscellaneous Commercial ServicesCommercial Services Institut National de Recherche Agronomique SA operates an agricultural research institute. The private company is based in Paris, France. and has subsidiaries in France. | Commercial Services |
EnobraQ SAS
EnobraQ SAS Chemicals: Major DiversifiedProcess Industries EnobraQ SAS develops yeast for the production of chemical compounds. The company was founded on November 13, 2015 and is headquartered in Ramonville-Saint-Agne, France. | Process Industries |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Health Technology |
Avantium Technologies BV
Avantium Technologies BV Miscellaneous Commercial ServicesCommercial Services Avantium Technologies BV operates as chemical technology company. It offers a breeding ground for revolutionary renewable chemistry solutions. The firm specializes in innovations and technologies for catalytic research and development services and systems. The company was founded in February 2000 and is headquartered in Amsterdam, the Netherlands | Commercial Services |
By Design Ltd.
By Design Ltd. Apparel/Footwear RetailRetail Trade By Design Ltd. owns & operates clothing and footwear stores. The company was founded in 1980 and is headquartered in Manchester, GB. | Retail Trade |
Microphyt SA
Microphyt SA BiotechnologyHealth Technology Microphyt SA researches, develops, produces and markets natural bioactive products from microalgae. Its solutions are intended to address the needs of personal-care, food and health-care industries worldwide, through a differentiated and sustainable approach and proprietary technologies allow controlled and industrial-scale supply of microalgae biomass and extracts. The firm''s Industrial scale photo bioreactors developed and patented and are designed to produce specific strains of microalgae by preserving cell integrity and yielding commercial quantities of slow-growing or biofilm-forming species. The company was founded by Arnaud Muller-Feuga in 2007 and is headquartered in Baillargues, France. | Health Technology |
- Stock Market
- Insiders
- Denis Lucquin
- Experience